menu
    • menu
    [{"orgOrder":0,"company":"Mosaic Therapeutics","sponsor":"Astex Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Licensing Agreement","leadProduct":"Beroterkib","moa":"ERK","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Mosaic Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Mosaic Therapeutics \/ Mosaic Therapeutics","highestDevelopmentStatusID":"7","companyTruncated":"Mosaic Therapeutics \/ Mosaic Therapeutics"},{"orgOrder":0,"company":"Mosaic Therapeutics","sponsor":"Syncona Limited","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2023","type":"Series A Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Mosaic Therapeutics","amount2":0.029999999999999999,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0.029999999999999999,"dosageForm":"Oral","sponsorNew":"Mosaic Therapeutics \/ Syncona Limited","highestDevelopmentStatusID":"4","companyTruncated":"Mosaic Therapeutics \/ Syncona Limited"}]

    Find Clinical Drug Pipeline Developments & Deals by Mosaic Therapeutics

    Menu

    Mosaic Therapeutics

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Mosaic Therapeutics

                            United Kingdom arrow
                            Peptide Process CMC
                            Not Confirmed

                            Mosaic Therapeutics

                            United Kingdom arrow
                            Peptide Process CMC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Beroterkib

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Recipient : Astex Pharmaceuticals

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Mosaic in-Licenses Two Oncology Programs from Astex for Combination Therapies

                            Details : Under the licensing agreement, Mosaic hold the rights of two clinical programs, which includes ASTX029 (beroterkib). It is being evaluated fr the treatment of neoplasms.

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            April 24, 2025

                            Lead Product(s) : Beroterkib

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Recipient : Astex Pharmaceuticals

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Mosaic Therapeutics

                            United Kingdom arrow
                            Peptide Process CMC
                            Not Confirmed

                            Mosaic Therapeutics

                            United Kingdom arrow
                            Peptide Process CMC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : Syncona Limited

                            Deal Size : $28.0 million

                            Deal Type : Series A Financing

                            DEALS_DEV arrow-down

                            Mosaic Therapeutics Closes $28m Series A Funding and Appoints Brian Gladsden as CEO

                            Details : The Series A funding will be used to further advance Mosaic’s pipeline of targeted oncology therapies for biomarker-stratified populations, progressing its lead programmes through preclinical development to IND-enabling studies.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Undisclosed

                            April 04, 2023

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : Syncona Limited

                            Deal Size : $28.0 million

                            Deal Type : Series A Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth